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ABSTRACT
Necrobiotic xanthogranuloma is an uncommon granulomatous disease involving the 
skin and extracutaneous tissues. It is characterized by indurated, yellow-red plaques and 
nodules, involving primarily the face and less frequently the trunk and extremities. The 
disease has a strong association with paraproteinemia and other hematologic or lym-
phoproliferative disorders. Histologically, the dermal part shows xanthogranulomatous 
change with extensive necrobiosis and many Touton and foreign-body giant cells. Here, we 
describe a case of a 46-year-old man with a 1-year history of multiple cutaneous lesions 
over the trunk and thighs. Necrobiotic xanthogranuloma was diagnosed by histology 
and clinically associated with paraproteinemia. This case is also unusual in that there 
was no periorbital involvement, which is believed to be a typical feature of this disease.
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Necrobiotic xanthogranuloma (NXG) is a rare destructive 
xanthogranulomatous disease classically involving the face, 
particularly the periorbital region, and the trunk. It has a 
chronic, progressive clinical course and is typically resist-
ant to treatment. NXG is closely associated with parapro-
teinemia with a monoclonal gammopathy. Other hematologic 
or lymphoproliferative diseases may also appear in associa-
tion with NXG.1,2 The clinical course is chronic and often 
progressive. Because of the rarity of this disease, we report 
a patient with the cutaneous and histological findings of NXG 
with associated monoclonal gammopathy. The lack of char-
acteristic involvement of the periorbital region in this patient 
is an unusual feature of this entity.
Case report
A 46-year-old man presented with a 1-year history of an-
nular plaques of various sizes with raised erythematous 
borders around a depressed center, on the trunk, arms, but-
tocks, and legs (Figure 1). The patient’s face was spared. The 
lesions began as indurated papulonodules, which slowly 
enlarged with advancing margins. The lesions were painful 
and became ulcerated. There were 12 lesions ranging from 
2 cm to 5 cm in diameter. Two of them were ulcerated. 
A skin biopsy was performed on the lesion located on the 
left thigh.
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Figure 1 (A,B) Multiple annular plaques with raised erythematous borders and central depressions on trunk, arms, buttock and legs.
Figure 2 Skin biopsy specimen from the left thigh showed extensive 
geographic necrobiosis surrounded by histiocytes, many multinucle-
ated giant cells, and lymphocytes throughout the dermis extending 
into deep subcutis (H&E, original magnification 40×).
Figure 3 Higher magnification of extensive necrobiosis and dense 
histiocytic infiltrate with multinucleate giant cells (H&E, original mag-
nification 100×).
Figure 4 Conspicuous xanthomatous histiocytes were seen in this 
field (H&E, original magnification 400×).
Histological examination revealed massive palisading 
granulomatous inflammation around the extensive geo-
graphic necrobiosis throughout the dermis extending into 
deep subcutis (Figure 2). The areas of necrobiosis were sur-
rounded by foamy histiocytes in addition to conspicuous 
giant cells (Figures 3 and 4), many of which were of the 
Touton type. Cholesterol clefts were also prominent (Figure 5). 
A diagnosis of NXG was made.
Laboratory investigation showed that the hemogram, test 
results for renal and liver function, fasting glucose levels, 
and lipid profiles were within normal ranges. Serum protein 
immunoelectrophoresis showed a monoclonal gammopathy 
of the IgG kappa type (IgG, 3350 mg/L; normal range: 700–
1600 mg/L). Bence-Jones proteins were not detected in urine. 
Examination of the bone marrow showed normal cellularity 
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patients, ulcerations occur early and are a prominent feature 
in most cases. NXG may also involve extracutaneous sites 
such as lung and heart.11,12 Thus, routine echography and dy-
namic cardiac imaging are recommended. Many laboratory 
abnormalities are associated with NXG. In about 75% of 
reported cases, protein electrophoresis demonstrated a 
monoclonal gammopathy, most commonly an IgG kappa 
light chain,1,12 as did the patient described here. Laboratory 
investigation also frequently showed elevated erythrocyte 
sedimentation rates, and about 50% of patients had leu-
kopenia and hypocomplementemia.12 Cryoglobulinemia 
has been found in approximately 40% of cases.2,12 Some 
patients also demonstrated positive results for antinuclear 
antibody and rheumatic factor.1,4 Serum cholesterol and 
trigly ceride levels do not correlate with the disease, and are 
usually normal.
The histopathological features of NXG are distinct and 
observed mainly in the deep dermis and the subcutaneous 
tissues. NXG is marked by granulomatous inflammation, 
which is composed of foamy histiocytes, lymphocytes, foreign-
body type multinucleated giant cells, and Touton giant cells 
alternating with collagen necrobiosis. Cholesterol clefts are 
usually observed within the necrobiotic foci12,13 and are 
characteristic of NXG. Our case also displayed cholesterol 
clefts, which are a helpful clue for the differential diagnosis. 
Nodular lymphoid aggregates are often reported in associa-
tion with the granulomas.13 The major histological differential 
diagnoses with NXG is necrobiosis lipoidica. The clinical 
lesions of necrobiotic lipoidica could be confused with NXG, 
especially when lesions of the latter are present over the 
pretibial lesions. However, necrobiosis lipoidica is usually 
not associated with any serum protein abnormalities. The pres-
ence of massive necrobiosis associated with numerous cho-
lesterol clefts, foamy histiocytes, bizarre multinucleated giant 
cells and Touton-type giant cells distinguishes necrobiotic 
xanthogranuloma from necrobiosis lipoidica.13 Cholesterol 
clefts are rarely seen in necrobiosis lipoidica. A review of 331 
cases of necrobiosis lipoidica, which extended over a 50-year 
period, identified only three cases with cholesterol clefts, 
and all were associated with severe diabetes mellitus.14
Given the high frequency of monoclonal gammopathy 
in patients with NXG, malignancies of the hematologic 
or lymphoproliferative type should be investigated. The 
most common associated malignancies are multiple mye-
loma, plasma cell dyscrasia and lymphoproliferative dis-
ease.12,15 Hematologic disorders may emerge before or after 
the onset of skin lesions (8 years before onset to at least 
11 years after onset).16 For this reason, patients with NXG 
require lifelong follow-up care. But low incidence of multi-
ple myeloma in the NXG population was noted ,which has 
a high incidence of paraproteinemia. In the largest and 
latest review by Spicknall and Mehregan12 in 2009, only 
3 NXG patients of the 70 reported since 1993 had multiple 
without an increase in the number of plasma cells. An ele-
vated erythrocyte sedimentation rate (73 mm/hr; normal range: 
0–15 mm/hr) was noted. Antinuclear antibody was positive at 
a low titer of 1:80. The C3 level was normal, but C4 levels 
were below 5.45 mg/L. Test results for rheumatic factor were 
negative, and cryoglobulin was not detected. Chest and skel-
etal X-rays were normal. Chest-abdominal-pelvic computed 
tomography was also negative.
This patient commenced with therapy of prednisolone 
40 mg daily for 1 week. The skin lesions showed improvement, 
concurrent with softening of the lesions, and ulcerative wounds 
ceased to enlarge. The prednisolone was tapered to the 
dose of 20 mg daily and used for 2 weeks. Then the condition 
was controlled with 10 mg prednisolone daily, with gradual 
improvement of the lesions. The paraprotein level remained 
unchanged. However, two new lesions on the patient’s left 
thigh appeared after 11 months of follow-up. Medium dose 
steroid (prednisolone 40 mg) therapy was re-initiated. Clinical 
condition was continually monitored.
Discussion
NXG was a rare condition and first recognized as a distinct 
entity by Kossard and Winkelmann in 1980.1 The characteristic 
clinical picture is of slowly progressive infiltrating xanthom-
atous plaques, typically affecting the periorbital region. The 
face, trunk, arms and upper thighs are also commonly in-
volved. A small number of patients without periorbital involve-
ment have been described.3−10 We reported another case of 
NXG in the absence of facial lesions. In reviewing the English 
literature of NXG patients who had no facial involvement, 
most patients presented with extensive lesions involving trunk, 
buttock and four extremities, as did our patient. In these 
Figure 5 Bands of necrobiosis with cholesterol clefts (arrow) with 
surrounding Touton giant cells (arrowhead) and foamy histiocytes 
(H&E, original magnification 400×).
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and histologically with other granulomatous and xanthom-
atous diseases. The prognosis of NXG depends on the sever-
ity of disease and the extent of extracutaneous involvement. 
We presented a patient with the histological and laboratory 
features of NXG. Unlike most patients with NXG, he did not 
have periorbital lesions at presentation. Because NXG is as-
sociated with a potentially life-threatening systemic disease, 
its recognition by the physician is important.
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There are many ways to treat NXG but they are often 
unsuccessful, and recurrences are frequent. Well-established 
therapeutic schemes are lacking because there have not 
been any randomized controlled trials. Chemotherapy with 
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